ページ3 - 最高の治療科医師 - トップ139名の医師

Professor Markus Dukes is a specialist in diagnostic radiology and minimally invasive therapy.

Awards

• Gold Medal of Honorary Professor of Osaka Medical University (Japan).
• Honorary member of DeGIR (German Society for Interventional Radiology and Minimally Invasive Therapy).

Education and professional experience

• 1982-1988 - study of human medicine at the Johannes-Gutenberg University in Mainz.
• 1988 - approval and medical license.
• 1988-1989 - Medical officer of the Bundeswehr.
• 1990 - Candidate of Medical Sciences in the field of radiology, subject: “Investigation of the influence of dilation speed on its success, as well as on damage to the vessel walls during balloon expansion”, at the Johannes-Gutenberg University in Mainz.
• 1990-1996 - Resident in the Department of Radiology at the Ruprecht-Karls University.
• 1996 - Senior physician in the Department of Radiodiagnostics at the Ruprecht-Karls University of Heidelberg.
• 1998 - Doctorate in Diagnostic Radiology, topic: "Direct comparison of imaging methods for gastric carcinoma: the importance of optimized examination methods in clinical practice and first experience with magnetic resonance imaging."
• 2000 - Deputy Head of the Department of Radiology, Department of Radiodiagnostics at the Ruprecht-Karls University of Heidelberg.
• 2000-2002 - Head of the Image Processing Center at the Orthopedic Clinic of the University of Heidelberg.
• 2002-2003 - Head of the Department of Radiology, Surgical Clinic, Department of Radiology at the Ruprecht-Karls University of Heidelberg.
• 2003 - Chief Physician of the Central Institute of Radiology and Neuroradiology at the Nordwest Clinic in Frankfurt am Main.
• 2006 - Associate Professor in the Department of Radiology at the University of Heidelberg.

Scientific activity

Marcus Dukes is one of the first physicians to perform minimally invasive microwave ablation of liver and lung tumors under CT guidance.

Clinical activities

The professor heads the first and only MRI-guided FUS ablation center in the Rhine-Main region. In most cases, the procedure allows avoiding surgical intervention. Patients of the center have access to ablation for prostate cancer, bone and liver metastases, benign tumors, and treatment of uterine fibroids without surgery.

Membership in organizations

• DRG (German Society of Radiologists).
• DeGIR (German Society for Interventional Radiology and Minimally Invasive Therapy).
• RSNA (Radiological Society of North America).
• ESGAR (European Society of Gastrointestinal and Abdominal Radiology).
• CIRSE (Cardiovascular and Interventional Radiology Society of Europe).
• ECR (European Congress of Radiology).
• EUFUS (European FUS Society).
• MEDICA (German Society for Interdisciplinary Medicine).

Assoc. Prof. Dr. Özlem Köroğlu is a specialist in Physical Medicine and Rehabilitation at Memorial Ankara Hospital (2024–present). She previously served as a faculty member at Gaziler Physical Therapy and Rehabilitation Training and Research Hospital (2016–2024). She was Chief of the Physical Medicine and Rehabilitation Clinic at Elazığ Military Hospital (2011–2015). She earned her MD in 2003 from the GATA Faculty of Medicine. She completed her PM&R residency in 2011.

Her credentials include Ministry of Health–approved certified prolotherapy training. She has taught Prolotherapy and PRP (2022) and Knee Prolotherapy and Campinject (2019). She also taught GETAT and Dextrose Prolotherapy (2018) and ISPRM Ultrasound (2009). She has additional training in musculoskeletal ultrasound, neural therapy, lumbar injections and manipulation, and botulinum toxin treatment for the spastic hand. She attended the Euro‑Mediterranean PRM School in Italy (2010). She is a member of the Turkish Society of PM&R, the Turkish Society for Research and Fight Against Rheumatism, the Association of PM&R Specialists of Türkiye, the Spinal Cord Diseases Association, and the Ankara Medical Chamber.

• Wang He Tian
• Head of the Department of Traditional Chinese Medicine
• Executive Director of the Beijing Association of Traditional Chinese Medicine
• Deputy Director of the Working Committee on the Inheritance and Development of Chinese Medicine, Chinese Medical Association
• Deputy Director of the Professional Committee of Chinese Medicine, Chinese Geriatric Society
• Secretary General of the Geriatric Committee of the Beijing Association of Traditional Chinese Medicine
• Permanent Member of the Professional Andrology Committee of Beijing Association of Integrative Traditional Chinese and Western Medicine
• Executive Director of the Andrology Department of the Society of Traditional Chinese Medicine
• Director of Beijing Medical Preventive Association
• Leading expert of the Beijing Group of Experts on Chinese Medicine
• Beijing's leading expert on traditional Chinese medicine and inheritance of academic experience
• Achievement Assessment Expert of the State Administration of Traditional Chinese Medicine
• Medical Director of Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
• Author and co-author of more than 10 clinical books on traditional Chinese medicine.
• Winner of the Beijing Science and Technology Commission Award for Scientific and Technological Progress in Clinical Research
• Deputy Director of the Department of Medical Affairs of Beijing Municipal Administration of Traditional Chinese Medicine

Achieved outstanding success in the treatment of the following pathologies:

• chronic inflammatory processes
• chronic dystrophic-degenerative processes
• diseases of the digestive system
• diseases of the spleen
• kidney disease
• prostate diseases
• sexual dysfunction
• female infertility
• urological diseases
• andrological diseases
• pathological processes accompanied by circulatory disorders and blood stagnation
• bedsores
• spinal diseases
• complex clinical cases
• intractable diseases
• rehabilitation treatment

Through rigorous training and practical experience, they have developed a deep understanding of Urology, earning recognition for their diagnostic skills and effective treatment approaches. Dr. Ahmet Tevfik Albayrak is a distinguished member of the European Society for Sexual Medicine (ESSM), a testament to their expertise and dedication in the field of sexual health. As a member of the ESSM, Dr. Ahmet Tevfik Albayrak remains connected to a network of professionals dedicated to advancing the field of sexual medicine. Their contributions to research, education, and clinical practice have earned them recognition from their peers and gratitude from the patients they serve. Furthermore, through their involvement with the ESSM, Dr. Ahmet Tevfik Albayrak stays abreast of the latest developments in sexual medicine, ensuring that they are equipped with the knowledge and skills needed to provide the highest quality of care to their patients. Their commitment to excellence and their compassionate approach to patient care continue to make a meaningful impact on the field of sexual health.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

An expert in microbial resistance and optimisation of the use of antimicrobials, he leads the Infectious Disease Unit of this hospital in Malaga.

Dr Javier Moreno Izarra is habitually involved in national and international scientific events. At the same time, he gives presentations that are specially focused on infectious disease in the area of antimicrobial resistance and in medical forums dedicated to the development of programs to optimise the use of antimicrobials.

Professional Experience:

• Head of the Internal Medicine Unit. Quirónsalud Marbella Hospital

• Head of the Internal Medicine Unit. Quirón Campo de Gibraltar Hospital

• Specialist of the Internal Medicine Unit. Alto Guadalquivir Hospital

• Specialist of the Internal Medicine Unit. Andújar Hospital

• Medical Coordination of the A&E Unit and Hospitalisation. High- resolution Hospital in Puente Genil

• Specialist of the Internal Medicine Unit. Costa del Sol Hospital

A member of:

• Spanish Society of Internal Medicine

• Spanish Society of Infectious Disease and Clinical Microbiology

• Spanish Society of Palliative Care

The Internal Medicine speciality is a branch of medicine that focuses on the diagnosis, treatment and prevention of diseases and conditions of adult patients. Internists of the Quirónsalud Marbella Hospital are experts in the comprehensive health care of their patients as they manage a broad range of medical conditions. The team of specialists of our Marbella hospital stands out for its comp rehensive approach and deep knowledge and skills relating to chronic disease. Their objective is to provide a high-quality medical service while guiding the patient and coordinating the actions against their diseases in close cooperation with the other specialists, if necessary, in order to obtain an adequate diagnosis and treatment. One fundamental part of the work of an internist is the management of chronical diseases such as diabetes, hypertension, heart and lung disease, amongst others.

These conditions often require follow-ups and adjustments to the treatment throughout time.

The Internal Medicine team does not only focus on the treatment of diseases, but also on their prevention. Internists work with their patients to identify the risk factors and promote healthy habits. 

Dr. Mustafa Emiroglu is a general surgery specialist at Memorial Bodrum Hospital. He has significant experience from his work at Sağlık Bilimleri University Tepecik SUAM (2016–2023) and Kırşehir Hospital (1997–1999).

He earned his medical degree from Istanbul University Cerrahpaşa Faculty of Medicine. He completed his specialization at Tepecik Training and Research Hospital. Dr. Emiroglu is a member of the Turkish Society of Surgery, the Endocrine Surgery Association, and the Colorectal Surgery Association.

He has attended advanced courses, including the Europe Senology Academia. He has also received training in proctologic, hemorrhoidal, and oncoplastic breast surgery, as well as thyroid diseases.

2002 – 2008 – Siriraj Medical School, Mahidol University

2008 – 2013 – Department of Internal Medicine, Rajavithi Hospital

2013 – 2015 – Department of Cardiology, Internal Medicine Rajavithi Hospital

2019 – 2020 – Cardiology Intervention, Department of Cardiology, Internal Medicine Rajavithi Hospital

Languages: English and Thai

Education and Expertise

• ISTANBUL UNIVERSITY FACULTY OF MEDICINE

Diseases

• Anxiety Disorder
• Bipolar Disorder
• Depression
• Obsessive Compulsive Disorders
• Panic Disorder
• Sematization
• Social Phobia
• Stress Disorder
• Schizophrenia

Treatment Methods

• Cognitive Therapy
• Individual Therapy
• Behavioral Therapy
• EMDR
• Interpersonal therapy
• Psychopharmacological
• Schema therapy

Experience

• Bakirkoy Prof. Dr. Mazhar Osman Mental and Nervous Diseases Training and Research Hospital

Academic Details

Faculty / University
19 Mayis University, Faculty of Medicine, Samsun – Turkey

Date of Graduation
1992

Postgraduate Training
Institution: Department of Radiology, Faculty of Medicine, Erciyes University, Kayseri – Turkey
Supervisor in Charge of Training: Mustafa Ozturk
Training Period: From 1993 to 1998
Title of Thesis: Evaluation of Lower Extremity Artery-Occlusive Disease by MR Angiography

Accreditation

Radiology Specialist: 1998, The Ministry of Health of Turkey

Associate Professor: 2003, Interuniversity Committee

Academic Experience

Residency: Department of Radiology, Erciyes University, Kayseri – Turkey (1993 to 1998)

Private Practice: Maternal and Children Hospital, Sivas – Turkey (1998–2000)

Academic Positions:

2000 to 2003: Assistant Professor of Radiology, Firat University, Elazig – Turkey

2003 to 2009: Associate Professor of Radiology, Firat University, Elazig – Turkey

2009 to 2010: Professor of Radiology, Firat University, Elazig – Turkey

2010 to 2015: Professor of Radiology, Chairman, Bezmialem Vakif University, Istanbul – Turkey

2015 to 2016: Professor of Radiology, Chairman, Yeditepe University, Istanbul – Turkey

2017 to Present: Professor of Radiology, Interventional Radiology Unit, Bahçelievler Medical Park Hospital, Altınbaş University, Istanbul – Turkey

Fellowship

Institution: Department of Radiology, University Hospital of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA

Duration:  2004 to 2005

Position: Research Fellow – Ultrasound & CT (Body)

Professional Memberships

-Turkish Society of Radiology

-Medical Ultrasound Society of Turkey

-Turkish Society of Radiology, Abdominal Radiology Study Group

-ESGAR – European Society of Gastrointestinal and Abdominal Radiology (Fellow)

-ESUR – European Society of Urogenital Radiology (Fellow)

-ESR – European Society of Radiology

-Turkish Society of Magnetic Resonance

-Turkish Society of Radiology, Urogenital Radiology Study Group

-Turkish Society of Interventional Radiology

-Korean Society of Radiology (International Member)

-Radiological Society of North America (RSNA) – Corresponding Member

Prizes and Awards

European Congress of Radiology (ECR) 2002, Vienna – Image Interpretation, 3rd Prize

Interpretation Corner of European Radiology 2003 – 2nd Prize

Cases of the Day – ESGAR 2007, Lisbon, Portugal – 2nd Prize

Cases of the Day – ESGAR 2009, Valencia, Spain – 1st Prize

Doctor of Osteopathy from National University of Medical Sciences – Registration S1702131.

Bachelor of science in Osteopathy from National University of Medical Sciences – Registration S1702131.

Certified from “Union of Thai Traditional Medicine Society” – Registration 112460.

Acupuncturist – Certified by Chinese Republic and signed by Notary – Registration 140013.

Member of the International Osteopathic Association (IOA).

Official representative of Osteopathy Chronic Pain Clinics of Canada (OCPCC) in Phuket – Thailand.

Gonstead Chiropractic techniques (inc Knee chest table).

Diploma in Osteopathic & Chiropractic full course online.

Certified Emergency first responder + CPR & AED (valid until 12/2026)

Member of the Swiss Medical Register (RME) – Registration B330879.

Member of the Association of Swiss Health Insurances - Registration 6178.

Certified in Chinese Pharmacology.

Certified in Chinese Psychiatric.

Certified in Chinese Nutrition.

 Posts and Affiliations

Clinical Director – Multidisciplinary Breast Unit Kliniken Essen-Mitte, Germany

Lead Breast Cancer Research Program, Kliniken Essen-Mitte

Executive Board Member of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)

 Additional Roles

ESMO Faculty – Breast Cancer

Member of AWO Gyn – Commission for plastic and reconstructive surgery

Speaker of the AGIMed – Commission for Integrative Medicine of the AGO

Member of the Organ Commission Mamma of the AGO

Scientific Director of the WSG study group

Global PI, Head of clinical investigations and trials 27

IDMC´s, Steering Boards national and international

Scientific committee of international and national symposia in breast cancer and surgical oncology

 Organization Memberships

Memberships: European Society of Medical Oncology, American Society of Clinical Oncology,

European Academy of Senology, German Cancer Society, German Society of Gynecology and

Obstetrics, Working Group for Gynecological Oncology, German Society of Senology,

 Publications

Peer reviewed Publications: 322

First/Senior Author: 38

h-Index/i10-Index 66/232

Congress Abstracts/Proceedings: 443

Books/Book Chapter: 59

Invited oral Presentations/Lectures: 1032

Professional activity

Dr. Borja Núñez de Aysa is the Director of the Ultrasound Interventional and Biological Therapies Unit at Olympia Quirónsalud. His appointment is a major development in the field of sports medicine, promising to take the institution to a new level of quality of care.

Medical career:

• More than 20 years of experience working with professional and amateur athletes.
• Specialization in the treatment and diagnosis of musculoskeletal injuries using ultrasound interventionism and regenerative technologies.
• Working in the medical service of prestigious clubs such as Atletico Madrid and Real Madrid , which highlights his deep understanding of the needs of elite athletes.

Special achievements:

• A recognized expert in the field of regenerative medicine, including the use of plasma rich in growth factors (PRGF) and stem cells .
• Implementation of innovative treatment methods that take sports medicine to a new level.

Education and specialization

• Faculty of Medicine, University of Alcalá (UAH):
  Graduated with first prize in the Objective Structured Clinical Evaluation (ECOE).
• Specialization:
  • Residency in Physical and Rehabilitation Medicine at the Puerta de Hierro Hospital, Majadahonda.
  • Continuous training and advanced training in the field of ultrasound diagnostics and interventional medicine.

Scientific interests and achievements

• Research in the field of regenerative medicine and development of new methods for treating musculoskeletal injuries.
• Conducting seminars, master classes and publishing scientific articles in reputable medical journals.
• Active collaboration with leading specialists, including close cooperation with the Olympia Quirónsalud Physiotherapy and Traumatology Department, headed by Dr. Manuel Lles.

Key Skills and Achievements

• Treatment of all types of sports injuries using visual control methods (ultrasound).
• A unique approach that provides personalized treatment for each patient, from diagnosis to recovery and prevention.
• Combining advanced technology and deep clinical experience to achieve the best results.

Contribution to sports medicine

Dr. Nunes de Aysa and his team have created one of the most modern departments in Europe, offering innovative and highly effective treatment methods. His work not only helps athletes recover faster from injuries, but also sets new standards in medical practice, making quality treatment available to every patient.

Education and Expertise

• 1998 – 2004 AZERBAIJAN UNIVERSITY MEDICAL UNIVERSITY
• 2016 – 2017 GAZİ UNIVERSITY FACULTY OF MEDICINE SPECIALIST TRAINING
• 2017 – 2022 EGE UNIVERSITY FACULTY OF MEDICINE SPECIALTY TRAINING

Diseases

• Attention Deficit Hyperactivity Disorder
• Autism

Experience

• 2004 -2005 Azerbaijan University Medical University, Department of Child Neurology
• 2005 – 2008 Baku City Hospital
• 2009 – 2012 Istanbul University Faculty of Medicine, Department of Child Neurology
• 2013-2015 Central Customs Hospital, Child Neurology, Baku
• 2022-2024 Izmir Private Can Hospital, Child-Adolescent Mental Health and Diseases

Professional Memberships

• ÇOGEPDER (Child Psychiatry Association)
• Association of Cognitive and Behavioral Therapies

Areas of activity: • Research of pathology in gerontological age group (elderly) patients • Clinical nutrition (enteral and parenteral nutrition) • Diabetes mellitus, metabolic syndrome, osteoporosis, thyroid diseases • Arterial hypertension • High body temperature of unknown genesis (fever) • Diseases of the musculoskeletal system, rheumatological diseases • Diseases of the gastrointestinal tract, liver • Disorders of water and electrolyte metabolism, kidney diseases Education: • Higher education - Azerbaijan Medical University, Faculty of General Medicine and Prevention, 2008-2014 • Specialization – Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine Work experience: • Baku State Hospital No. 3, resident physician nephrologist. 2014-2016 • Istanbul Private Bahcelievler Memorial Hospital, specialist in internal medicine. 2021-2022 Research work: (dissertation / defense) • Clinical and laboratory features of patients with acute interstitial nephritis diagnosed during kidney biopsy, factors influencing the etiology and response to treatment. Istanbul University, Istanbul Faculty of Medicine, Department of Nephrology, 2021 Publications:(2) •P343Efficacy of adalimumab mild-to-moderate inflammatory bowel disease: Real-life data from a single-centre experience in the long-term period. January 2020 Journal of Crohns and Colitis DOI: 10.1093/ecco-jcc/jjz203.472 •Concurrent myelomatous pleural effusion and extramedullary mediastinalinvolvement as a relapse manifestation of multiple myeloma. Abstract of the IXth International Eurasian Hematology OncologyCongress17–20October2018Istanbul,Turkey(Concomitant myelomatous pleurisy and extramedullary mediastinal lesion as a recurrent manifestation of multiple myeloma. Abstracts of the IX International Eurasian Oncohematology Congress17–20October2018Istanbul,Türkiye) Memberships in scientific organizations: •Turkish Medical Association